These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8004569)

  • 21. Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
    Huang CH; Hsieh HH; Wang JM; Hsu K; Yang WC; Yu TJ
    J Formos Med Assoc; 1992 Jul; 91(7):699-703. PubMed ID: 1360298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.
    Huang HS; Su HY; Li PH; Chiang PH; Huang CH; Chen CH; Hsieh MC
    Sci Rep; 2018 May; 8(1):7485. PubMed ID: 29748589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association.
    Inokuchi J; Naito S; Fujimoto H; Hara T; Sakura M; Nishiyama H; Miyazaki J; Kikuchi E; Hinotsu S; Koie T; Ohyama C;
    Int J Urol; 2016 Mar; 23(3):224-30. PubMed ID: 26659912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
    Sengeløv L; Kamby C; Geertsen P; Andersen LJ; von der Maase H
    Cancer Chemother Pharmacol; 2000; 46(5):357-64. PubMed ID: 11127939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
    Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
    Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A clinical study concerning survival of operative cases for the transitional cell carcinoma of the upper urinary tract].
    Yumura Y; Fujikawa A; Tajiri T; Kawai M; Yokomizo Y; Moriyama M; Noguchi S; Ogo Y; Kobayashi K; Senga Y; Fujinami K; Yamashita Y; Okajima K
    Hinyokika Kiyo; 2009 Feb; 55(2):65-70. PubMed ID: 19301609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
    Small EJ; Lew D; Redman BG; Petrylak DP; Hammond N; Gross HM; Eastham JA; Crawford ED
    J Clin Oncol; 2000 Jul; 18(13):2537-44. PubMed ID: 10893284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.
    Taguchi S; Nakagawa T; Hattori M; Niimi A; Nagata M; Kawai T; Fukuhara H; Nishimatsu H; Ishikawa A; Kume H; Homma Y
    Jpn J Clin Oncol; 2013 Sep; 43(9):923-8. PubMed ID: 23888082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
    Chun HG; Dorr FA
    Cancer Treat Res; 1989; 42():151-74. PubMed ID: 2577102
    [No Abstract]   [Full Text] [Related]  

  • 35. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.
    Fujita K; Inamoto T; Yamamoto Y; Tanigawa G; Nakayama M; Mori N; Tsujihata M; Azuma H; Nonomura N; Uemura M
    Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
    Mead GM; Russell M; Clark P; Harland SJ; Harper PG; Cowan R; Roberts JT; Uscinska BM; Griffiths GO; Parmar MK
    Br J Cancer; 1998 Oct; 78(8):1067-75. PubMed ID: 9792152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.
    Douglas J; Sharp A; Chau C; Head J; Drake T; Wheater M; Geldart T; Mead G; Crabb SJ
    Br J Cancer; 2014 Apr; 110(7):1759-66. PubMed ID: 24556622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma.
    Miyazaki Y; Kosaka T; Mikami S; Kikuchi E; Tanaka N; Maeda T; Ishida M; Miyajima A; Nakagawa K; Okada Y; Sato Y; Oya M
    Clin Cancer Res; 2012 Aug; 18(15):4145-53. PubMed ID: 22675166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.